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Abstract 26 
 27 
Most of the current commercial probiotic strains have not been selected 28 
for specific applications, but rather on the basis of their technological potential 29 
for use in diverse applications. Therefore, by selecting them from appropriate 30 
sources, depending on the target population, it is likely that better performing 31 
strains may be identified. Few strains have been specifically selected for human 32 
neonates, where the applications of probiotics may have a great positive 33 
impact. Breast-milk constitutes an interesting source of potentially probiotic 34 
bifidobacteria for inclusion in infant formulas and foods targeted to both pre-35 
term and full-term infants. In this study six Bifidobacterium strains isolated from 36 
breast-milk were phenotypically and genotypically characterised according to 37 
international guidelines for probiotics. In addition, different in vitro tests were 38 
used to assess the safety and probiotic potential of the strains. Although clinical 39 
data would be needed before drawing any conclusion on the probiotic 40 
properties of the strains, our results indicate that some of them may have 41 
probiotic potential for their inclusion in products targeting infants. 42 
 43 
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Introduction 51 
 52 
Probiotics are defined as live microorganisms which when administered in 53 
adequate amounts confer a benefit on the host (FAO/WHO, 2006). Different 54 
microorganisms are currently used as human probiotics; among them 55 
Lactobacillus and Bifidobacterium constitute the most frequently used genera. 56 
Most of the current commercial probiotic strains have not been selected for 57 
specific applications but rather selected on the basis of their technological 58 
potential. Nevertheless, it is well known that probiotic effects are strain specific, 59 
therefore it is very likely that better performing strains may be selected when a 60 
rational, use-specific selection process is followed. The selection of strains from 61 
appropriate sources depending on the target population, such as neonates, 62 
children, pregnant women or the elderly, whose microbiota may differ from that 63 
of healthy adults (O’Toole and Claesson, 2010), may constitute a promising 64 
approach. In this regard most of the strains currently available have targeted the 65 
adult population but few strains have been selected for other groups of age, 66 
such as human neonates, where the applications of probiotics may have a great 67 
positive impact (Salminen et al., 2009). 68 
Microbial colonization of the neonate gut is a stepwise process that 69 
provides important signals for the maturation of the immune system and the 70 
development of the intestine (Cebra, 1999; Stappenbeck et al., 2002), thus 71 
greatly contributing to the establishment and maintenance of the gut barrier 72 
(Penders et al., 2006; Rakoff-Nahoum et al., 2004). Aberrancies in this process 73 
can predispose to disease in later life (Kalliomaki et al., 2001, 2008). Thus, 74 
initial microbial colonization provides an important starting point for the later 75 
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homeostasis and well-being of the individual. One of the factors having a strong 76 
influence in this process is the feeding habits of the infant (Harmsen et al., 77 
2000), with breast-feeding constituting the golden standard for infant nutrition. In 78 
fact, the protective effect of breast-feeding on allergies, diarrhoea or respiratory 79 
infections has been shown in different studies (Björksten et al., 2001; Majamaa 80 
et al., 1995). One of the main differences observed between breast and 81 
formula-fed infants is the composition of the gut microbiota, with bifidobacteria 82 
constituting the most predominant microorganisms in the former group. 83 
Increasing bifidobacterial levels is often considered a target in the development 84 
of infant formulas (Agget et al., 2003). Traditionally, the higher level of 85 
bifidobacteria observed in breast-fed infants has been attributed to the presence 86 
of bifidogenic oligosaccharides in breast-milk (Aggett et al., 2003). Also, more 87 
recently the presence of bifidobacteria in breast-milk has been reported 88 
(Gueimonde et al., 2007a; Martín et al., 2009; Solis et al., 2010), which may 89 
also play a role in the dominance of this microorganism observed in breast-fed 90 
infants. This fact has directed attention towards the supplementation of infant 91 
formulas. However, most of the strains currently used were not isolated from the 92 
natural source but from the commercially available strains. The inclusion of 93 
breast-milk bifidobacteria in formulas targeted at both pre-term and full-term 94 
infants constitutes a very promising area for the development of new products 95 
aiming at the establishment of a healthy gut microbiota and a proper intestinal 96 
barrier resembling that of breast-fed infants. 97 
In a previous study (Solis et al., 2010) we isolated three Bifidobacterium 98 
longum and three Bifidobacterium breve strains from breast-milk. Now we aim 99 
to identify these isolates at strain level by using different phenotypic and 100 
5 
 
genotypic methods as well as to characterise them by using different in vitro 101 
tests following the FAO/WHO guideline recommendations (2006).  102 
 103 
Material and Methods 104 
 105 
Strains and growth conditions 106 
Six Bifidobacterium strains, B. longum IPLA 20001, 20002 and 20003 and 107 
B. breve IPLA 20004, 20005 and 20006, previously isolated from breast-milk of 108 
five healthy mothers (Solis et al., 2010) were included in this study. B. longum 109 
strains IPLA 20002 and 20003 were isolated from breast-milk of the same 110 
women at different time points (10 days and 1 month postpartum, respectively). 111 
The other four strains were isolated from different women at different times; B. 112 
longum IPLA 20001 at 1 day postpartum, B. breve strains IPLA 20004 and 113 
20005 at 1 month and B. breve IPLA 20006 at 3 months postpartum. The 114 
strains were routinely grown in MRS medium (Difco, Becton-Dickinson and 115 
Company, Le Pont de Claix, France) supplemented with a 0.25% L-cysteine 116 
(Sigma Chemical Co, St. Louis, MO, USA) (MRSc) and using anaerobic 117 
incubation conditions (10% H2, 10% CO2 and 80% N2) in a chamber Mac 500 118 
(Don Whitley Scientific, West Yorkshire, UK) at 37ºC. The pathogens used in 119 
the different experiments were Clostridium difficile DSMZ 12056, Salmonella 120 
enterica subsp. enterica serovar. Typhimurium LMG 15860, Cronobacter 121 
sakazakii LMG 5740 (formerly Enterobacter sakazakii LMG 5740), Shigella 122 
sonnei LMG 10473 and Staphylococcus aureus CECT 435. These pathogenic 123 
microorganisms were selected due to their role as pathogens for humans and 124 
their presence in the human gut. For the experiments of in vitro growth 125 
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inhibition, the strains of Shigella, Salmonella and Cronobacter were grown in 126 
Nutrient Agar plates, whilst for Clostridium and Staphylococcus the agar media 127 
used were Brain Heart Infusion (BHI) (Oxoid Ltd., Basingstoke, Hamshire, 128 
England) and Trypticase Soy Broth (TSB) (Oxoid), respectively. Clostridium 129 
difficile was grown at 37ºC under anaerobic conditions whereas the other 130 
pathogens were grown in aerobiosis at 32ºC for Cronobacter and at 37ºC for 131 
the remaining microorganisms.  132 
For adhesion to mucus experiments, all the bacteria were grown in Gifu 133 
Anaerobic Medium (GAM) broth (Nissui Pharmaceutical CO., Tokio, Japan) and 134 
incubated at 37°C under anaerobic conditions. In adhesion and competitive 135 
exclusion assays, bacteria were grown for 18 h, harvested, and then washed 136 
twice with phosphate-buffered saline (PBS) buffer. Microorganisms were 137 
metabolically labelled by the addition of 10 L/mL tritiated thymidine (5-3H-138 
thymidine 1.0 mCi/mL, Amersham Biosciences, UK) to the media.  139 
The widely used probiotic Bifidobacterium animalis subsp. lactis Bb12 was 140 
included in the tolerance to acid and bile as well as adhesion assays for 141 
comparison purposes. 142 
 143 
Species identity of bifidobacterial strains by partial sequence analysis of the 144 
16S rRNA gene.  145 
The strains were identified at species level by partial sequence analysis of 146 
the 16S rRNA gene. DNA was extracted from 1 mL of culture by using the 147 
GenElute™ Bacterial Genomic DNA Kit (Sigma) following the manufacturer’s 148 
instructions. 16S rDNA was amplified using Bifidobacterium specific primers 149 
Bif164 and Bif662 as indicated elsewhere (Ruas-Madiedo et al., 2005). 150 
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Amplified PCR products were purified using the GenElute™ PCR clean-up Kit 151 
(Sigma) and sequencing of the amplicons was done at Secugen SL (Madrid, 152 
Spain) in an automated sequencer ABI Prism (Applied Biosystems, Foster City, 153 
CA, USA). The sequences obtained were compared with those held at the 154 
databases by using BLAST (Altschul et al., 1997). 155 
 156 
Genetic typing of strains  157 
Randomly amplified polymorphic DNA (RAPD)-PCR. DNA extracts were 158 
employed for breast-milk bifidobacteria typing by RAPD-PCR using previously 159 
described conditions and the primer 5’-TGCCGAGCTG-3’ (Mättö et al., 2004) 160 
(Sigma Genosys). PCR reactions were run in a UnoCycler VWR-ADTM (VWR 161 
Internacional Eurolab S.L, Spain) thermocycler. Amplification products were 162 
subjected to electrophoresis in 1% agarose (Sigma) and gels were stained and 163 
visualized by ethidium bromide staining. 164 
DNA restriction patterns by pulsed-field gel electrophoresis (PFGE). Intact 165 
high molecular weight genomic DNA was isolated and digested in agarose 166 
plugs. Cells were grown to an OD600 of 1.5, harvested by centrifugation, washed 167 
three times in buffer TE pH 8.0 (10 mM Tris-HCl, 1 mM EDTA pH 8.0) and 168 
resuspended in 500 L of the same solution. To form agarose plugs, the cell 169 
suspension was heated to 50ºC, mixed with an equal volume of 2 % PFGE 170 
agarose (Bio-Rad Laboratories, Richmond, Ca., USA) in 0.5X TBE buffer and 171 
added to moulds. Plugs were incubated for 24 h at 37ºC in 1 mL of lysis buffer 172 
(per plug) containing 50 mM EDTA pH 8.0, 0.5 mg/mL N-laurylsarcosine, 5 173 
mg/mL Brij58, 2 mg/mL deoxicholate, 2 mg/mL lysozyme, 15 U/mL mutanolysin 174 
and 2 µg/mL RNase and then deproteinized by incubation at 50ºC for 24 h in a 175 
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solution containing 0.5 M EDTA pH 8.0, 40 mM Tris-HCl pH 8.0, 1% w/v SDS 176 
and 1.5 mg/mL proteinase K (all reagents were purchased from Sigma). They 177 
were finally washed for 1 h in TE and incubated for 24 h at 37ºC in TE pH 8.0 178 
containing 0.29 mg/mL pefabloc SC (Merck, Darmstadt, Germany). 179 
Thin slices of agarose plugs were cut and washed six times for 30 min at 180 
room temperature in TE buffer. DNA within the plugs was digested with 20 U of 181 
the restriction enzyme XbaI. Electrophoresis was carried out at 6 V/cm and 182 
14ºC using a CHEF DRII apparatus (Bio-Rad) in 1 % PFGE certified agarose 183 
(Bio-Rad) gels with 0.5 x TBE buffer. Pulse times ranged from 2 to 25 s during 184 
the 22 h electrophoresis. A DNA pulse marker (LowRange PFG Marker 185 
N0350S, New England Biolabs, Ipswich, MA, USA) was used as the molecular 186 
size standard. Gels were stained and visualized by ethidium bromide staining.  187 
 188 
Characterization of strains by enzymatic and carbohydrate fermentation profiles 189 
Fermentation profiles of strains were obtained in API 50 CH strips (Bio-190 
Mérieux, Marcy l’Etoile, France) following the manufacturer’s instructions. 191 
Enzymatic activity profiles were determined using API Zym strips (Bio-Mérieux).  192 
 193 
Antibiotic resistance profiles 194 
The minimal inhibitory concentration (MIC) of the strains towards 195 
gentamicin, kanamycin, streptomycin, neomycin, tetracycline, erythromycin, 196 
clindamycin and chrolamphenicol was determined by the microdilution method 197 
using the microtiter VetMIC Lact-1 panel for susceptibility testing of bacteria 198 
(Statens Veterinarmedicinska Anstalt, Uppsala, Sweden). The Standard 199 
Operating Procedure (SOP) proposed by the EU funded ACE-ART project, and 200 
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currently being evaluated for approval as an international standard by the 201 
ISO/IDF working group (ISO/DIS 10932|IDF 223), was followed. In brief, strains 202 
were grown in MRSc agar, colonies were resuspended in LSM medium (90% 203 
Isosensitest medium [Oxoid] + 10% MRS medium [Difco]) supplemented with 204 
0.3 g/L-cysteine to OD600nm 0.2 and the suspension was diluted 1000 times in 205 
the same medium. 100 µL were then added to each microtiter plate well and 206 
incubated at 37ºC under anaerobic conditions for 48 hours. Growth within each 207 
well was determined visually after incubation. 208 
 209 
Tolerance to acid and bile 210 
Five mL bacterial cultures were grown overnight at 37ºC under anaerobic 211 
conditions. Then, cells were harvested, washed twice with 0.85% NaCl and 212 
resuspended in 500 µL of the same solution. 100 µL of bacterial suspensions 213 
were added to 900 µL of simulated gastric juice (125 mM NaCl, 7 mM KCl, 45 214 
mM NaHCO3, and 3 g/L pepsin [Sigma], adjusted to pH 2.5 with HCl) or bile 215 
juice (45 mM NaCl, 1 g/L pancreatin [Sigma] and 3 g/L Oxgall [Sigma], adjusted 216 
to pH 8.0 with NaOH). Suspensions were then incubated in anaerobiosis for 90 217 
or 180 min with acid and bile juices, respectively. Plate counts in MRSc were 218 
done at time 0 and after incubation and results represented as % of survival. 219 
 220 
In vitro inhibition of pathogen growth 221 
The ability of the supernatants from the Bifidobacterium strains to inhibit 222 
the growth of pathogenic microorganisms was determined using the agar 223 
diffusion tests by measuring the diameter of the inhibition zones.  224 
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Five mL samples were taken from growing cultures of the bifidobacterial 225 
strains at two different growth phases; exponential (OD between 1 and 2) and 226 
stationary (OD between 4 and 5, depending on the strain). After centrifugation, 227 
supernatants were divided in two aliquots, one was adjusted to pH 6.2 and the 228 
other one left unadjusted. Supernatants were then stored at -20ºC until use in 229 
the agar diffusion tests. 230 
Overnight (16 h) pathogen cultures were used to inoculate (1% v/v) agar 231 
media, 5 mm wells were cut out of the agar and 25 µL of each supernatant were 232 
added to the well. Tetracycline (100 µg/mL) was used as a positive control. 233 
Plates were then incubated for 24 h under appropriate conditions for each 234 
specific pathogen. After incubation the diameter of the inhibition zone, if any, 235 
was measured. Two independent replicates were conducted for each 236 
experiment. 237 
 238 
Adhesion to HT29 cell line  239 
The adhesion capability of the strains was assessed with the epithelial 240 
intestinal cell line HT29 (ECACC No. 91072201), derived from human colon 241 
adenocarcinoma, purchased from the European Collection of Cell Cultures 242 
(Salisbury, UK). The cell line was maintained in McCoy’s medium supplemented 243 
with 10% (v/v) heat-inactivated bovine foetal serum and a mixture of antibiotics 244 
to give a final concentration of 50 µg/mL penicillin, 50 µg/mL streptomycin, 50 245 
µg/mL gentamicin, and 1.25 µg/mL amphotericin B. All media and supplements 246 
were obtained from Sigma. The incubations took place at 37ºC, 5% CO2 in an 247 
SL Water-jacketed CO2 Incubator (Sheldon Mfg. Inc., Cornelius, Oregon, USA). 248 
Culture media were changed every two days and the cell line was trypsinized 249 
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with 0.25% trypsin-EDTA solution (Sigma) following standard procedures. For 250 
experiments, 105 cells/mL were seeded in 24-well plates and incubated to 251 
confluence (reaching about 107 cells/mL) during 13±1 days.   252 
Bacterial cultures were harvested by centrifugation, washed twice with 253 
Dulbecco’s PBS buffer (Sigma) and resuspended in McCoy’s medium without 254 
antibiotics at a concentration of about 108 cfu/mL. HT29 monolayers were 255 
washed twice with Dubelco’s PBS to remove the antibiotics before adding the 256 
bacterial suspensions. Plates were incubated for 1 h at 37°C, 5% CO2 in a 257 
Heracell 240 incubator (Thermo Electron LDD GmbH, Langenselbold, 258 
Germany). After the incubation period, supernatants were discarded and wells 259 
were softly washed three times with Dulbecco’s PBS buffer to remove the non-260 
attached bacteria. Afterwards, the monolayers were trypsinized and bacterial 261 
counts were carried out in agar-MRSc to determine the number of adhered 262 
bacteria. Results were expressed as the percentage of bacteria adhered with 263 
respect to the amount of bacteria added (% cfu bacteria adhered / cfu bacteria 264 
added). Experiments were carried out in replicate (using two HT29 plates) and 265 
in each plate the strains were also tested in duplicate.   266 
 267 
Adhesion to human infant mucus  268 
Human intestinal mucus was obtained from 2 and 6-month-old infant 269 
faeces as described earlier (Kirjavainen et al., 1998). Mucus was dissolved (0.5 270 
mg protein/mL) in HEPES-Hanks buffer (HH; 10 mM HEPES, pH 7.4). 271 
Radiolabeled bacteria optical density (OD600 nm) was adjusted to 0.25 ± 0.05 to 272 
standardize the bacterial concentration (108 bacteria/mL). The adhesion 273 
assessment was carried out as previously described (Gueimonde et al., 2005). 274 
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Adhesion was expressed as the percentage of radioactivity recovered after 275 
adhesion relative to the radioactivity of the bacterial suspension added to the 276 
immobilized mucus. Adhesion was determined in three independent 277 
experiments, and each assay was performed in triplicate to calculate intra-278 
assay variation. 279 
 280 
Inhibition of pathogen adhesion to infant mucus 281 
To test the ability of the bifidobacteria to inhibit the adhesion of pathogens, 282 
the procedure described by Collado et al. (2005) was used. In brief, unlabeled 283 
bifidobacteria (108 bacteria/mL) or HH buffer (control) were added to the wells 284 
and incubated for 1 h at 37°C and wells were washed twice with HH buffer (to 285 
remove unattached bifidobacteria in the corresponding wells). Radiolabeled 286 
pathogens (108 bacteria/mL) were then added to the wells and incubated at 287 
37°C for 1 h. The wells were then washed and bound bacteria were recovered 288 
after lysis. Radioactivity was measured by liquid scintillation. The percentage of 289 
adhesion inhibition was calculated as the change in the adhesion of the 290 
pathogen in the presence of the different bifidobacterial strains with regard to 291 
that in the control (set arbitrarily to value zero). Inhibition was determined in 292 
three independent experiments and each assay was performed in duplicate. 293 
 294 
Statistical analysis 295 
Data were statistically analysed using the SPSS 11.0 software for 296 
Windows (SPSS Inc., Chicago, IL, USA). One-way ANOVA tests were 297 
performed to determine differences among strains. When appropriate the post-298 
hoc mean comparison LSD test was additionally used.  299 
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Results 300 
 301 
Identification at species level 302 
The partial 16S rDNA sequences obtained from the amplification products 303 
confirmed the identity of the strains previously determined by using another 304 
primer pair (Solis et al., 2010). The sequences obtained are held at Genbank 305 
database under deposit numbers HM856586 to HM866591. 306 
 307 
Genotypic and phenotypic characterisation of the strains 308 
The six bifidobacterial strains were genotyped by using two different 309 
methods. The RAPD profiles obtained allowed us to distinguish the strain B. 310 
breve IPLA 20006 from the other two B. breve strains, which showed identical 311 
profiles, and B. longum IPLA 20001 from the other two B. longum strains, which 312 
also showed the same RAPD profile (Figure 1a). PFGE macro-restriction 313 
showed identical profiles for the strains B. breve IPLA 20004 and IPLA 20005, 314 
these being different from that of B. breve IPLA 20006 (Figure 1b), and allowed 315 
distinguishing among the three B. longum strains, including those 316 
indistinguishable by RAPD (IPLA 20002 and IPLA 20003). Overall, RAPD 317 
produced four different profiles, whilst PFGE showed a higher discriminatory 318 
power establishing five different profiles. 319 
With regard to the phenotypic characterisation, none of the six 320 
Bifidobacterium strains fermented glycerol, erythiol, D-arabinose, L-xylose, D-321 
adonitol, methyl-βD-xylopyranoside, L-sorbose, L-rhamnose, dulcitol, inositol,  322 
methyl-αD-mannopyranoside, methyl-αD-glucopyranoside, N-acetyl-323 
glucosamine, amygdalin, arbutin, D-cellobiose, D-trehalose, inulin, starch, 324 
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xylitol,  D-lyxose, D-fucose, L-fucose, D-arabitol, L-arabitol, gluconate, 2-325 
ketogluconate or 5-ketogluconate. All the strains fermented D-ribose, D-326 
galactose, D-glucose, D-maltose, D-lactose, D-mellibiose, D-saccharose and D-327 
raffinose. In addition, only the three B. longum strains were able to ferment L-328 
arabinose and D-xylose whilst aesculin was only fermented by the B. breve 329 
strains. The results obtained for those sugars showing variability within each 330 
species are shown in Table 1. Sugar fermentation profiles allowed 331 
distinguishing between two B. breve strains (IPLA 20004 and IPLA 2005), which 332 
showed identical RAPD and PFGE profiles, and corroborates previous reports 333 
indicating a higher discriminatory power for the combination of phenotypic and 334 
genotypic techniques than for the genotypic methods alone (Gueimonde et al., 335 
2004). 336 
Analysis of enzymatic activity profiles of the six Bifidobacterium isolates 337 
showed that -fucosidase, as well as the harmful -glucuronidase activity, were 338 
not present in any strain, whilst all microorganisms presented high levels (≥ 30 339 
nanomoles, results not shown) of leucine arylamidase, -galactosidase, -340 
glucosidase and -galactosidase activities. The presence of this last activity 341 
was in accordance with the capacity of these microorganisms to ferment 342 
raffinose. The three B. longum strains lacked -glucosidase activity which was 343 
present on the B. breve strains. Enzymatic activities showing variability are 344 
shown in Table 1.  345 
 346 
Antibiotic resistance profiles of the strains 347 
B. longum strains showed higher resistance levels than B. breve, although 348 
strain-specific variability was found (Table 2). The strain B. longum IPLA 20001 349 
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showed resistance to erythromycin (4 µg/mL) and clindamycin (>16 µg/mL), 350 
eight and over 50 times higher, respectively, than that found for any of the other 351 
strains tested. 352 
 353 
Tolerance to acid and bile 354 
The widely used probiotic strain B. lactis Bb12 was included for reference 355 
and comparison purposes. Tolerance to low pH was highly variable. B. lactis 356 
Bb12 showed the highest stability in simulated gastric juice with 74.5% survival 357 
after 90 min of exposure (Table 3). Among the tested strains B. breve IPLA 358 
20006 displayed the highest survival (23.36%) whilst the recovery of all the 359 
other strains was less than 1.5%. Interestingly, simulated bile juice was more 360 
toxic than the gastric juice. In fact, survival percentages after exposure for 180 361 
min to bile juice were lower than 1% for all the strains tested. B. longum IPLA 362 
20003 showed the highest survival with a 0.84% whereas the reference strain 363 
B. lactis Bb12 survived only a 0.0004% after bile juice challenge. When the 364 
results of tolerance to both gastric and bile juices are taken together it appears 365 
that the strain B. longum IPLA 20003 has the highest ability to survive during 366 
gastrointestinal transit, this being even higher than that of the reference strain 367 
B. lactis Bb12. 368 
 369 
In vitro inhibition of pathogen growth 370 
The inhibition ability of supernatants from the different bifidobacterial 371 
strains against some pathogens was determined by the agar diffusion test. The 372 
positive control used (tetracycline) produced inhibition zones for all pathogens 373 
with diameters ranging from 14 to 29 mm. No inhibition was observed for any of 374 
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the supernatants in which the pH was neutralized (results not shown). None of 375 
the Bifidobacterium non-neutralized culture supernatants inhibited the growth of 376 
St. aureus or C. difficile (results not shown). For the other three pathogens 377 
tested, inhibition was found for some of the non-neutralized stationary phase 378 
bifidobacterial cultures supernatants (Table 4). S. enterica was inhibited by non-379 
neutralized supernatants of B. longum IPLA 20002, B. longum IPLA 20003, B. 380 
breve IPLA 20004 and B. breve IPLA 20005, but not by those of B. longum 381 
IPLA 20001 and B. breve IPLA 20006. Similarly, all non-neutralized stationary 382 
phase culture supernatants, except that of B. breve IPLA 2006, inhibited the 383 
growth of Sh. sonnei and all of them were able to inhibit Cr. sakazakii growth. 384 
This last microorganism was, in addition, inhibited by the non-neutralized 385 
exponential phase supernatants from B. longum IPLA 20002 and B. breve IPLA 386 
20005 (diameter of the inhibition zones: 8 mm), these being the only cases in 387 
which inhibition was observed for exponential growth phase culture 388 
supernatants (results not shown).  389 
 390 
Adhesion to intestinal epithelial cells  391 
Adhesion ranged between 0.1 and 5.5% depending on the strain, with 392 
some of the breast-milk strains adhering significantly better (p<0.05) than the 393 
reference strain B. lactis Bb12 (Figure 2). 394 
 395 
Adhesion to human infant mucus  396 
B. longum IPLA 20001 was the strain showing a significantly better 397 
adhesion to 2-month-old infant mucus (55.3%) (Figure 3). When 6-month-old 398 
infant mucus was used, B. longum IPLA 20002 and B. breve IPLA 20005 399 
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showed significantly higher adhesion values than the other strains. The strain B. 400 
breve IPLA 20004 showed the lowest adhesion values in both models (2 and 6-401 
month-old infant mucus). Interestingly, strains B. longum IPLA 20001, B. breve 402 
IPLA 20006 and the reference strain B. lactis Bb12 adhered significantly better 403 
to mucus from 2-month-old infant than to that obtained from 6-month-old 404 
infants.  405 
 406 
Inhibition of adhesion of pathogens to human intestinal mucus 407 
The adhesion of the pathogens tested on 2 and 6-month-old infant mucus 408 
was 3.27±0.51 and 3.23±0.79 %, respectively, for S. enterica, 1.69±0.48 and 409 
3.83±1.25 % for Cr. sakazakii, 13.21±2.18 and 12.50±1.62 % for Sh. sonnei, 410 
3.49±1.09 and 5.19±1.10 % for St. aureus and 4.26±0.21 and 4.86±0.53 % 411 
respectively, for C. difficile. Cr. sakazakii adhered significantly better (p<0.05) to 412 
mucus isolated from 6-month-old infants than that from 2-month-old babies. 413 
The ability of the breast-milk bifidobacterial strains to inhibit the adhesion 414 
of the pathogens to infant intestinal mucus was determined (Figure 4). B. lactis 415 
Bb12 was also included for comparative purposes. All the bifidobacterial strains 416 
increased significantly the adhesion of S. enterica to infant mucus in at least 417 
one of the two models (2 and 6-month-old infants), with increases ranging from 418 
4 to 210% when compared to the control (buffer without bifidobacteria). The 419 
reference strain B. lactis Bb12 caused the highest increase in the adhesion of 420 
the pathogen, 210 and 177% in 2 or 6-month-old infant mucus, respectively. 421 
None of the strains affected significantly the adhesion of Sh. sonnei in these 422 
mucus models. B. breve IPLA 20004 and B. lactis BB12 increased significantly 423 
the adhesion of C. difficile to 2-month-old infant mucus (22 and 31%, 424 
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respectively) whilst B. breve IPLA 20006 increased the adhesion of the 425 
pathogen to 6-month-old infant mucus. Similarly, B. longum IPLA 20001 and 426 
IPLA 20003 as well as B. lactis Bb12 significantly increased the adhesion of St. 427 
aureus to 2-month-old infant mucus, whereas no effect was found with the other 428 
strains tested, or in the 6-month-old infant mucus model. The adhesion of Cr. 429 
sakazakii to 2-month-old infant’s mucus was significantly increased (70%) by 430 
the reference strain B. lactis Bb12, whilst B. breve IPLA 20005 significantly 431 
reduced (43.4%) the adhesion of this pathogen in that model. This was the only 432 
case in which the adhesion of a pathogen was significantly inhibited by one of 433 
the strains tested. 434 
 435 
Discussion 436 
 437 
Human breast-milk constitutes an interesting source to obtain new and 438 
specific probiotic strains for neonates aiming at assisting a proper development 439 
of the gut microbiota and the immune development in infants who, for different 440 
reasons, cannot be breast-fed.  441 
Here we confirmed the identity of six Bifidobacterium strains, previously 442 
isolated from breast-milk (Solis et al., 2010), by partial sequencing of the 16S 443 
rRNA gene. Three of the strains were identified as B. longum and the other 444 
three as B. breve. These strains were typified and characterised by using 445 
phenotypic and genotypic tests. A step-wise process was used to this end 446 
following the guidelines established by the FAO/WHO working group 447 
(FAO/WHO, 2006), which recommends to carry out strain identification by 448 
phenotypic and genotypic methods as well as in vitro functional characterization 449 
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and safety assessment before enrolling on clinical trials. In accordance with 450 
previous studies, genetic typing techniques have shown a high discriminatory 451 
power with PFGE showing a higher resolution than RAPD (Mättö et al., 2004). 452 
Our results are in good agreement with previous reports (Gueimonde et al., 453 
2004) indicating that the combination of genotypic and phenotypic methods 454 
extended the discriminatory power of the former alone, as shown with the B. 455 
breve strains IPLA 20004 and IPLA 20005 which displayed identical genetic 456 
profiles but different phenotypic traits. In addition, phenotypic tests provide data 457 
on the specific properties and the metabolic potential of the strains related to 458 
functionality and safety. The presence of potentially deleterious enzymatic 459 
activities may, sometimes, be a concern and it was also checked. The 460 
enzymatic activity profiles of our strains indicate the absence of potentially 461 
deleterious activities such as β-glucuronidase, related to the conversion of pre-462 
carcinogens to carcinogens. 463 
In addition to proper strain identification it is always important to pay 464 
attention to safety. B. longum and B. breve are considered safe and have QPS 465 
status according to EFSA (EFSA, 2007). However, when identifying and 466 
characterizing new strains it is always advisable to take into account any 467 
potential safety concern. Several reports have underlined the importance of 468 
establishing antibiotic resistance profiles, which have become mandatory in 469 
some countries (Health Canada, 2009). For these reasons we determined the 470 
antibiotic resistance profiles of our strains. In general, the antibiotic resistance 471 
levels observed are in the range of those previously reported for these species 472 
(ISO10932/IDF223; Kushiro et al., 2009; Mättö et al., 2007). Intrinsic resistance 473 
to aminoglycosides (streptomycin and gentamicin) is normally present in 474 
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bifidobacteria due to the anaerobic nature of these microorganisms (Mättö et 475 
al., 2007) and the subsequent lack of cytochrome-mediated transport (Bryan 476 
and Kwan, 1981). According to the breakpoint values established by EFSA for 477 
antibiotic resistance in the genus Bifidobacterium (EFSA, 2008) one of the B. 478 
longum strains included in this study (IPLA 20001) presented resistance to 479 
erythromycin (4 µg/mL versus breakpoint for Bifidobacterium of 0.5 µg/mL) and 480 
clindamycin (>16 µg/mL versus breakpoint of 0.25 µg/mL). The presence of 481 
resistance to these two antibiotics in the same strain has been previously 482 
reported and suggests a common resistance mechanism against both 483 
antibiotics. It is known as the macrolide-lincosamide-streptogramin (MLS) 484 
phenotype and in a recent study this phenotype was found in 7 out of 17 B. 485 
longum strains tested (Ammor et al., 2008). The MIC for tetracycline obtained 486 
for the three B. longum strains was also above the breakpoint established by 487 
EFSA (EFSA, 2008) for this antibiotic in the genus Bifidobacterium (16 µg/mL  488 
versus breakpoint value of 8 µg/mL). This suggests the possible presence of 489 
tetracycline resistance genes, such as tet(W) which has been reported to be 490 
commonly present in this species (Ammor et al., 2008). The genetic basis and 491 
potential transferability of these resistances, even if they are common in B. 492 
longum, require further clarification. It is worth commenting that strains showing 493 
high non-transferable resistance to certain antibiotics provide an interesting tool 494 
for co-administration with antibiotics, in order to stabilize the microbiota, 495 
potentially avoiding certain side-effects of antibiotics, such as associated 496 
diarrhoea. On the contrary, strains harbouring transferable resistances should 497 
not be used. 498 
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It is also important to determine in vitro potential probiotic properties of the 499 
strains before engaging in long and expensive clinical trials. Tolerance to 500 
gastrointestinal transit (acidic pH in the stomach and bile in the small intestine), 501 
antimicrobial activity, as well as the ability to adhere to the human intestinal 502 
mucosa are among the most frequently used selection tests.  503 
Survival in simulated gastric juice and in the presence of simulated bile 504 
juice were independently determined as indicators of the survival potential of 505 
the strains during gastrointestinal transit. The tolerance to gastric juice was 506 
highly variable, B. lactis Bb12 being the strain showing higher survival followed 507 
by B. breve IPLA 20006. Bile juice was more toxic than acidic conditions, B. 508 
longum IPLA 20003 showing the highest survival. Combining the results of both, 509 
acid and bile tolerance, B. longum IPLA 20003 appears to display the highest 510 
ability to survive during gastrointestinal transit. Nevertheless, the relevance of 511 
these tests in the selection of probiotics for application in neonates is not clear 512 
as newborns have a reduced acid and bile secretion (Bhat et al., 1997; 513 
Lebenthal and Lebenthal, 1999) and, therefore, even strains not showing a 514 
good in vitro tolerance may perform well in the in vivo situation. 515 
The production of antimicrobial compounds against pathogens by breast-516 
milk isolates was determined using the agar diffusion test. St. aureus and C. 517 
difficile were not inhibited by any of the bifidobacterial supernatants. Inhibition of 518 
S. enterica, Sh. sonnei and Cr. sakazakii was obtained with non-neutralized 519 
supernatants from some of the bifidobacterial strains, whilst no inhibition was 520 
observed for any of the supernatants in which the pH had been neutralized. 521 
This indicates that most likely the inhibition was due to the production of organic 522 
acids. In addition, supernatants taken from stationary growth phase cultures 523 
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were more inhibitory than supernatants from exponential growth, supporting the 524 
role of acid production in such inhibition. 525 
Adhesion to human intestinal mucus has been shown to vary depending 526 
on the age of the host (Ouwehand et al., 1999). Because of this we decided to 527 
use in the present work, in addition to the HT29 cell line, mucus from infants as 528 
they constitute a very clear target in the human population for breast-milk 529 
probiotic strains. The two adhesion models used (HT29 vs. infant mucus) 530 
clearly showed different results. In fact, the strain showing higher adhesion to 531 
HT29 cells, B. breve IPLA 20004, was found to be the less adhesive to infant 532 
mucus. Interestingly, all B. breve strains and B. longum IPLA 20001 adhered 533 
significantly better to HT29 cells than the reference strain B. lactis Bb12, 534 
considered a highly adhesive strain. The same is true for the strain B. longum 535 
IPLA 20001 when mucus obtained from 2-month-old infants was used, this 536 
strain showing the highest adhesion. These results indicate good adhesion 537 
ability for some of the breast-milk Bifidobacterium strains included in this study. 538 
In this regard, the strain B. longum IPLA 20001 was isolated from breast-milk 539 
from a 1-day old baby’s mother and isolates showing identical PFGE profiles 540 
were also found in the infant faeces at 1, 10 and 30 days of age (results not 541 
shown), which suggests a good colonization ability for this strain. 542 
The mucus adhesion levels observed for the reference strain B. lactis 543 
Bb12 are comparable to those reported by other authors using infant mucus 544 
(Juntunen et al., 2001). In general, the adhesion values obtained are slightly 545 
higher than those usually found when using intestinal mucus isolated from 546 
adults (Collado et al., 2005; He et al., 2001), which corroborates previous 547 
results showing that adhesion to intestinal mucus varies depending on the age 548 
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or health status of the mucus donor (Ouwehand et al., 1999, 2003). Higher 549 
adhesion of some Bifidobacterium strains to 2-month-old than to 6-month-old 550 
infant mucus, or to mucus isolated from adults or elderly subjects, has 551 
previously been reported (Ouwehand et al., 1999), supporting our findings of 552 
higher adhesion of some strains in mucus of younger infants.  553 
In accordance with previous reports (Collado et al., 2005; Gueimonde et 554 
al., 2007b) the inhibition of pathogens’ adhesion was found to be rather specific, 555 
depending on both the bifidobacterial strain and the pathogen used. 556 
Interestingly, some Bifidobacterium strains seemed to increase the adhesion to 557 
infant intestinal mucus of some of the pathogens tested, suggesting that 558 
bifidobacteria may facilitate the adhesion of pathogens through their attachment 559 
to the bifidobacterial cells. Increases in the adhesion of pathogens to human 560 
mucus in the presence of bifidobacteria and lactobacilli have previously been 561 
reported (Collado et al., 2005; Gueimonde et al., 2006, 2007b). However, the 562 
biological significance of this phenomenon is unknown, it is possible that the 563 
pathogen adhered to the bifidobacteria is no longer available to invade the 564 
mucosa. Only one of the strains tested (B. breve IPLA 20005) was able to 565 
significantly inhibit the adhesion of one of the pathogens tested (Cr. sakazakii) 566 
in the 2-month-old infant mucus model, whereas none of the strains was 567 
inhibitory in the 6-month-old infant mucus model. 568 
In short, in this study we characterised phenotypically and genotypically 569 
six Bifidobacterium strains isolated from breast-milk according to international 570 
guidelines for probiotics. In addition, different in vitro tests were used to assess 571 
the probiotic potential of these strains. Although clinical data would be needed 572 
before any conclusion on the probiotic properties of the strains can be drawn, 573 
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our results demonstrate that some of the tested strains isolated from breast-milk 574 
may have good probiotic potential for their inclusion in products targeting 575 
infants. 576 
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Table 1. Carbohydrate fermentation and enzymatic activities (expressed as 744 
nanomoles according to the API Zym strips manufacturer) demonstrating 745 
variability among  the strains included in this study. 746 
 747 
 Strain 
 B. longum B. breve 
 
IPLA 
20001 
IPLA 
20002 
IPLA 
20003 
IPLA 
20004 
IPLA 
20005 
IPLA 
20006 
Carbohydrate       
D-fructose - + + + + + 
D-mannose - - - - - + 
D-mannitol - + + + + - 
D-sorbitol - + + + + - 
Salicin - - - - - + 
D-melezitose + - - - - - 
Glycogen - - - - + - 
Gentiobiose - - - + - - 
D-turanose - + + + + + 
Enzymatic activity       
Alkaline phosphatase 0 0 5 5 5 5 
Esterase (c4) 30 20 20 20 20 10 
Esterase lipase (c8) 30 10 10 30 20 10 
Lipase (c14) 0 5 5 5 5 5 
Valine arylamidase 10 10 10 20 10 10 
Cystine arylamidase 20 20 20 30 10 5 
Trypsin 0 0 0 5 0 5 
α-chymotrypsin 5 0 0 0 0 5 
Acid phosphatase 30 ≥40 ≥40 ≥40 30 20 
Naphthol-AS-BI-phosphohydrolase 10 10 5 10 10 10 
β-glucosidase 0 0 0 20 10 ≥40 
N-Acetyl-β-glucosaminidase 20 30 30 30 30 30 
α-mannosidase 30 20 20 5 5 10 
 748 
 749 
 750 
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Table 2. Antibiotic resistance profiles. MICs (µg/mL) obtained for the different 751 
bifidobacterial strains included in this study. 752 
Strain GE KA ST NE TE ER CL CH 
B. longum IPLA 20001 16 256 16 32 16 4 >16 1 
B. longum IPLA 20002 32 512 64 128 16 0.5 0.12 2 
B. longum IPLA 20003 64 512 64 >256 16 0.5 0.12 2 
B. breve IPLA 20004 2 64 2 16 1 0.12 0.12 1 
B. breve IPLA 20005 8 256 4 64 1 0.25 0.25 0.5 
B. breve IPLA 20006 32 256 32 64 2 0.12 0.06 1 
GE, gentamycin; KA, kanamycin; ST, streptomycin; NE, neomycin; TE, 753 
tetracycline, ER, erythomycin, CL, clindamycin, CH, chloramphenicol  754 
 755 
 756 
 757 
 758 
 759 
 760 
 761 
 762 
 763 
 764 
 765 
 766 
 767 
 768 
 769 
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Table 3. Percentage of survival of bifidobacterial strains after 90 or 180 min of 770 
exposure to simulated gastric or bile juices, respectively. 771 
 772 
Strain Tolerance to gastric 
juice 
(Mean ± sd) 
Tolerance to bile 
juice 
(Mean ± sd) 
B. longum IPLA 20001 0.1625 ± 0.025 0.0006 ± 0.0004 
B. longum IPLA 20002 0.2445 ± 0.050 0.0018 ± 0.0013 
B. longum IPLA 20003 0.9235 ± 0.132 0.8400 ± 0.1318 
B. breve IPLA 20004 0.0160 ± 0.009 0.0002 ± 0.0001 
B. breve IPLA 20005 1.1940 ± 0.486 <0.00001 
B. breve IPLA 20006 23.3580 ± 6.644 <0.00001 
B. lactis Bb12 74.5000 ± 4.950 0.0004 ± 0.0002 
 773 
 774 
 775 
 776 
 777 
 778 
 779 
 780 
 781 
 782 
 783 
 784 
 785 
 786 
 787 
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Table 4. In vitro inhibition of the growth of pathogens by the bifidobacterial 788 
strains tested. Results display the diameter of the inhibition zones (mm) 789 
obtained for the stationary growth phase non-neutralized supernatants from 790 
the Bifidobacterium strains and the corresponding pH values. 791 
 792 
 793 
 794 
 795 
 796 
 797 
 798 
 799 
 800 
 801 
 802 
 803 
 804 
 805 
 806 
 Diameter (mm) of inhibition zones 
Strain IPLA 
20001 
IPLA 
20002 
IPLA 
20003 
IPLA 
20004 
IPLA 
20005 
IPLA 
20006 
pH 4.5 4.3 4.4 4.3 4.3 4.5 
Cr. sakazakii 10 11 10 11 11 12 
Sh. sonnei 11 13 10 8 10 0 
S. enterica 0 10 12 11 10 0 
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Figure 1. (a) RAPD-PCR profiles obtained for the B. breve (A) and B. longum 807 
(B) strains included in this study. A: Lane 1, molecular weight marker; lane 2, 808 
IPLA 20005; Lane 3, IPLA 20006; Lane 4, IPLA 20004. B: Lane 1, molecular 809 
weight marker; lane 2, IPLA 20001; lane 3, IPLA 20002; lane 4, IPLA 20003. (b) 810 
PFGE macrorestriction profiles obtained with XbaI for the Bifidobacterium 811 
strains included in this study. Lanes: 1, molecular weight marker; 2, B. longum 812 
IPLA 20001; 3, B. breve IPLA 20004; 4, B. breve IPLA 20005; 5, B. longum 813 
IPLA 20002; 6, B. longum IPLA 20003; 7, B. breve IPLA 20006. 814 
 815 
Figure 2. Percentage of adhesion to HT29 cells of the Bifidobacterium strains  816 
included in this study and the control strain B. lactis Bb12. (ANOVA, p = 0.000). 817 
Bars with different letters differ significantly (p<0.05; LSD test). 818 
 819 
Figure 3. Percentage of adhesion to intestinal mucus, from 2 month old (black 820 
bars) and 6 month old (white bars) infants, of the Bifidobacterium strains 821 
included in this study and the control strain B. lactis Bb12. Bars with different 822 
letters within the same mucus group (2 or 6 months) differ significantly (both 823 
cases ANOVA, p = 0.000) (p<0.05; LSD test). Asterisks indicate statistically 824 
significant differences between adhesion of the strain to mucus from 2 or 6 825 
month-old infants (p<0.05). 826 
 827 
Figure 4. Inhibition of the adhesion of model pathogens to intestinal mucus 828 
isolated from 2 month-old (black bars) or 6 month-old (white bars) infants by the 829 
bifidobacteria tested and the control strain B. lactis Bb12. An asterisk indicates 830 
strains which significantly modified the adhesion with regard to the 831 
36 
 
corresponding 2 or 6 month mucus control (HH buffer without bifidobacteria, 832 
arbitrarily set to value zero). Positive values indicate increases in the adhesion 833 
of the pathogens whilst negative values indicate inhibition of adhesion. Results 834 
are expressed as mean values, coefficients of variation ranged between 2 and 835 
19%. 836 
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Figure 3. Arboleya et al.
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Figure 4. Arboleya et al.
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